Study objective: The goal of this study is to assess the safety and tolerability of an inner ear infusion of CGF166, a gene therapy. Another goal is to assess the effectiveness of CGF166 by measuring changes in hearing before and after treatment. Some of the possible benefits that researchers believe CGF166 may provide include improved hearing that may be revealed as improved speech recognition, and the ability to benefit from a hearing aid and avoid the need for a cochlear implant.
Am I eligible? Participants should be 21 to 70 years of age with severe hearing loss in both ears. You will be unable to participate if your hearing loss was caused by genetic/developmental disorders, surgery, or trauma. Also, participants will be excluded if they have cochlear implants, Meniere's disease, or immunodeficiency diseases.
More about Pioneers Recruitment Registry
University of Kansas Medical Center (KUMC)
Related News Article: